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TABLE 1. Sample of long-term published studies
Valve type Reference
Mean
follow-up (y)
Maximum
follow-up (y) Determination of SVD
Biocor Myken and
Bech-Hansen2
6.0 aortic,
6.2 mitral
20 Reoperation for SVD
Mitroflow Yankah et al3 4.1 21 Reoperation for SVD
PERIMOUNT Biglioli et al4 6 18 Prosthesis replacement for SVD
PERIMOUNT Aupart et al5 5.5 18 Echocardiography indicated
by mean gradient>40 mm Hg
Carpentier-Edwards
S.A.V. porcine valve
Jamieson et al6 7.8 20 Reoperation and pathology reports from autopsy, or
echocardiography in patients with reduced functional class
Hancock II Borger et al7 7.4 (0–21) 20 Clinically relevant stenosis or regurgitation per
echocardiographic documentation or reoperation
PERIMOUNT Edwards
LifeSciences8
9 20 Explant for SVD
SVD, Structural valve deterioration.
Letters to the Editorechocardiograms for all patients
(because of old age and various other
reasons). Studies that report freedom
from all SVD generally have very
few patients reported with SVD who
do not undergo reoperation. It thus is
most unlikely that their numbers truly
reflect all SVD. In our opinion, it is
more fair to report SVD leading to re-
operation, because it is an objective
measurement. Suyker and Leicher1
have noted the uneven age distribution
with time, with older mean age in the
last decade than in the first. This re-
flects a trend in cardiovascular surgery
in which the average age of patients
receiving heart valves during the past
20 years has increased. As an example
from one of your references, Aupart
and colleagues5 reported a mean age
of 72.6 years in 2006. The same group
had published in 1996 on the same set
of patients with a mean age of 67.5
years.9 Suyker and Leicher1 also com-
ment on incompleteness in our table
showing long-term survival and dura-
bility outcomes (17–20 years) of
large-scale (n>1000 patients) studies
of bioprosthetic heart valves for aortic
valve replacement. We have never
claimed that this table is complete.
As pointed out in our article, it is
difficult to compare outcomes in
populations with differing baseline
characteristics, and different reports
rarely include all the same baseline
characteristics. With that as a back-The Journalground, the table only illustrates
a snapshot of the available data and
was reported as such.
Again, we thank them for their in-
terest in our publication.
Pia Myken, MD, PhD
Odd Bech-Hansen, MD, PhD
Department of Thoracic and
Cardiovascular Surgery
Sahlgrenska University Hospital
G€oteborg, SwedenReferences
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OUTCOME IN THE
TRANSECTION OF THE
PULMONARYARTERYAND
VEIN:
To the Editor:
We thank Dr Kamiyoshihara and
colleagues1 for bringing Dhaliwal and
colleagues’ study2 to our attention.
The content was both interesting and
clinically relevant. Understanding that
transection of the main pulmonary ar-
tery does not mandate continued resec-
tion is an invaluable piece of
information, but should only be used
when a patient is in extremis, warrant-
ing immediate transfer from the operat-
ing room.
We disagree with their conclusions
concerning vein ligation based on their
experience with a single case. Early
data suggest that ligation of both the
superior and inferior veins results in
death.3 However, other studies suggestry c Volume 141, Number 2 597
Letters to the Editorthat ligation of a single pulmonary
vein, either superior or inferior, may
be accompanied by dilation of collat-
eral veins to the azygous system,which
may be compatiblewith life.4 This area
requires further study, and conclusions
should not be based a single case.
In surgical emergencies, a transected
main pulmonary artery does not pre-
clude abrupt abortion of the intended
surgical procedure. However, this
should be used as a last resort. In elec-
tive cancer cases, a thorough inspection
of all structures including artery, veins,
and bronchus should be undertaken to
ensure resectability before transection
of any individual major structure.
Raja M. Flores, MD
Chief of Thoracic Surgery
Mount Sinai School of Medicine
New York, NY
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FENESTRATE
To the Editor:
In their recent article, Salazar and
colleagues1 have rightly addressed
a pertinent topic. We agree that under
usual circumstances a fenestration at
the time of a total cavopulmonary
connection should be avoided. Be-
tween June 2000 and June 2006, a total
of 132 consecutive patients were
treated at our institution without any
fenestrations. At the time of total cav-
opulmonary connection, 93 patients
(70%) were younger than 48 months.
We continue to complete at a young598 The Journal of Thoracic and Cage and to avoid fenestrations. We
have since opted for fenestration in
only 2 patients, both of whom under-
went single-lung palliation.
Salazar and colleagues1 state that
they opted for fenestration only in
‘‘highly selected patients.’’ They men-
tion patients with elevated pulmonary
vascular resistance or transpulmonary
gradient, significant atrioventricular re-
gurgitation, and single-lung physiol-
ogy. We would appreciate further
guidance on their selection criteria, be-
cause we would like to know their cut-
off for elevated pulmonary vascular
resistance and why they deem patients
with atrioventricular regurgitation to
be candidates for fenestration. In addi-
tion, why should any intracardiac anat-
omynot be amenable to an extracardiac
completion? In our view, the extracar-
diac completion does in fact help to
overcome many complex morphologic
obstacles and helps make it quite easy
to reroute central venous blood flow
to the pulmonary vascular bed.
Salazar and colleagues1 might also
elucidate their experience with fenes-
tration patency. Ruiz and colleagues2
have published an intriguing concept
in which the lower atrial orifice toward
the divided inferior vena cava is su-
tured in an end-to-side fashion to the
leftward aspect of thepunched conduit.
Christian Schreiber, MD, PhD
J€urgen H€orer, MD, PhD
R€udiger Lange, MD, PhD
Department of Cardiovascular
Surgery
German Heart Center Munich at the
Technical University
Munich, Germany
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HYPERLACTATEMIA AFTER
SURGICAL REPAIR OF
SECUNDUM ATRIAL SEPTAL
DEFECT IN CHILDREN: WHAT
IS THE PROBLEM?
To the Editor:
We read with great interest the arti-
cle by Abraham and colleagues.1 They
report their results of a retrospective
study on the intraoperative risk factors
for early postoperative hyperlactate-
mia in patients undergoing atrial sep-
tal defect repair. Multivariate logistic
regression analysis showed that lower
cardiopulmonary bypass (CPB) flow
rate is an independent risk factor for
early postoperative hyperlactatemia
in children after atrial septal defect re-
pair. It has instructive significance for
the perfusionist to maintain higher
mixed venous saturations and use va-
sodilators during CPB to improve
overall tissue perfusion.
The study includes 68 patients with
atrial septal defect, Risk Adjustment
for Congenital Heart Surgery category
I, who had good cardiac output in the
postoperative period. This effectively
avoids the influence of confounding
factors on blood lactate, such as the
CPB temperature, hemodilution, du-
ration of CPB, cardiac function, drugs
used perioperatively, liver and kidney
function, and so forth. The design is
a benefit for the study of the correla-
tion simply between intraoperative
factors and postoperative hyperlacta-
temia. However, several other factors
that influence the blood lactate should
be considered.
The subjects have atrial septal de-
fect and are aged less than 21 years
(range, 5–201 months). The age span
is comparatively large because there
is a big difference in the CPB prime
and management between those aged
5 months and those aged 201 months.
Generally, children aged less than 1
year would be primed with banked
red blood cells and have compara-
tively more banked blood periopera-
tively. Banked blood itself, which
